EBS:NYSE
Emergent Biosolutions Inc
$6.91
arrow_downward
-1.22%(-0.085) 1D
$6.91
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 13, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
$6.95
High
$7.07
Low
$6.85
Mkt. cap
354.30M
Avg. vol.
1.15M
Volume
575.79K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.28
Shares outstanding
51.27M
No. of employees
900
Open
$6.95
High
$7.07
Low
$6.85
Mkt. cap
354.30M
Avg. vol.
1.15M
Volume
575.79K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.28
Shares outstanding
51.27M
No. of employees
900
News stories
From web sources and news partners
bloomingbit
·
24 minutes ago
New York Stocks Close Lower; Nasdaq Falls 0.15%
Invezz
·
11 minutes ago
Dow closes 170 pts lower as chip stock sell off continues
Kearney Hub
·
5 minutes ago
What is the Russell 2000 index, and how does it compare to the S&P 500 and Nasdaq 100?
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteemergentbiosolutions.com